Asset Details
Do you wish to reserve the book?
Cannabinoid receptor 2 as a novel target for promotion of renal cell carcinoma prognosis and progression
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cannabinoid receptor 2 as a novel target for promotion of renal cell carcinoma prognosis and progression
Do you wish to request the book?
Cannabinoid receptor 2 as a novel target for promotion of renal cell carcinoma prognosis and progression
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cannabinoid receptor 2 as a novel target for promotion of renal cell carcinoma prognosis and progression
2018
Overview
Purpose
Renal cell carcinoma (RCC) is the most common malignancy of urogenital system, and patients with RCC may face a poor prognosis. However, limited curable therapeutic options are currently available. The aim of this study is to investigate the role of Cannabinoid receptor 2 (CB2) in RCC progression.
Methods
Immunohistochemistry was to investigate the expression pattern of CB2 in 418 RCC tissues and explore its prognostic function in RCC patients. Furthermore, the role of used CB2 si-RNA knockdown and inhibited by AM630, a CB2 inverse agonist, on cell proliferation, migration, and cell cycle of RCC cell lines in vitro was also investigated.
Results
We observed that CB2 was up-regulated in RCC tissues, and presented as an independent prognostic factor for overall survival of RCC patients and higher CB2 expression tends to have poor clinical outcomes in survival analyses. Moreover, we also observed that CB2, incorporated with pN stage, pathological grade, and recurrence or distant metastasis after surgery, could obviously enhance their prognostic accuracy in a predictive nomogram analysis. In addition, knockdown or inhibition by AM630 for the expression of CB2 in vitro could significantly decreased cell proliferation and migration, and obviously induced cell cycle arrest in G2/M of RCC cells.
Conclusions
CB2 expression is functionally related to cellular proliferation, migration, and cell cycle of RCC cells. Our data suggest that CB2 might be a potential therapeutic target for RCC.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Adult
/ Aged
/ Carcinoma, Renal Cell - genetics
/ Carcinoma, Renal Cell - metabolism
/ Carcinoma, Renal Cell - pathology
/ Carcinoma, Renal Cell - therapy
/ Cell Movement - drug effects
/ Cell Proliferation - drug effects
/ Cell Proliferation - physiology
/ Female
/ G2 Phase Cell Cycle Checkpoints - drug effects
/ Humans
/ Kidney Neoplasms - metabolism
/ Kidney Neoplasms - pathology
/ M Phase Cell Cycle Checkpoints - drug effects
/ Male
/ Medicine
/ Oncology
/ Original Article – Cancer Research
/ Receptor, Cannabinoid, CB2 - antagonists & inhibitors
/ Receptor, Cannabinoid, CB2 - biosynthesis
/ Receptor, Cannabinoid, CB2 - deficiency
/ Receptor, Cannabinoid, CB2 - genetics
/ RNA
/ Studies
/ Surgery
